Non-inferior drugs from Korea innovative pharmaceutical companies will likely be eligible for preferential drug pricing starting next year.

Previously, non-inferior drugs were priced below the weighted average of alternative drugs. However, through improvement measures, if the patent of an alternative drug is still active, non-inferior drugs are now likely to be priced within a range between the weighted average price and the highest price of alternative drugs.

According to the industry, the government and the pharmaceutical industry held a meeting for ‘Measures to Recognize the Appropriate Value of Innovative Drugs,’ and shared these updates.

The improved measure